Safety of 6 Hours Feeding After Extracorporeal Shock Wave Lithotripsy of Pancreatic Stone

NCT05669573 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 216

Last updated 2025-03-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of eating 6 hours after Extracorporeal Shock Wave Lithotripsy (ESWL). At present, ESWL and Endoscopic Retrograde Cholangiopancreatography (ERCP) are the routine ways to treat pancreatic duct stones. For large stones (diameter \> 5mm) , ESWL often needs to be performed many times. In clinical practice, fasting for 24 hours after surgery is often used, but long-term fasting brings strong discomfort to patients. However, the consensus for initiation timing of oral nutrition has not yet been established after ESWL. Thus, we design this trial to evaluate the safety of early feeding based on 6 hours parameter instead of the consensus definition.

Conditions

  • Pancreatic Duct Stone
  • ESWL
  • Fasting

Interventions

PROCEDURE

Early feeding group

Patients in the early diet group started oral intake 6 hours after ESWL of the day of procedure with a soft diet comprised 200 mL with 170 kilocalories.

PROCEDURE

Standard fasting group

Patients in the standard fasting group were fasted for 24 hours after the first ESWL operation, and close observation during this fasting period.

Sponsors & Collaborators

  • Ruijin Hospital

    collaborator OTHER
  • Shanghai Pudong New Area Gongli Hospital

    collaborator OTHER
  • First People's Hospital of Hangzhou

    collaborator OTHER
  • LanZhou University

    collaborator OTHER
  • The Second Affiliated Hospital of Baotou Medical College

    collaborator OTHER
  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Liang-hao Hu, MD · Changhai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-29
Primary Completion
2024-04-17
Completion
2024-04-22

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05669573 on ClinicalTrials.gov